Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest 10-K

View Latest 10-K

Stock Information


Nasdaq: DMPI




52 week Low/High

Day Low/High

Company Overview

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors.


DelMar Pharmaceuticals, Inc.
12707 High Bluff Drive
Suite 200
San Diego, CA, United States 92130

Investor Relations

T: (604) 629-5989

Transfer Agent

Mountain Share Transfer, LLC
2030 Powers Ferry Road SE
Suite #212
Atlanta, Ga. 30339
United States
T: 404-474-3110
F: 404-816-8830